利多卡因输注治疗神经病理性疼痛的疗效与安全性:随机双盲安慰剂对照研究
主要结局为末次输注后11点NRS疼痛评分较基线的百分比变化。结果显示利多卡因组末次输注后NRS百分比下降显著大于对照组(P=0.011),但4周随访时该差异未检出,且无严重并发症。
要点
- 利多卡因3 mg/kg输注可短期缓解难治性神经病理性疼痛,末次输注后NRS降幅优于安慰剂(P=0.011)。
- 重复输注后第3、4次镇痛差异更明显,但4周随访时疼痛缓解未持续。
- 研究中未发生严重并发症。
核心结论
- 利多卡因输注(3 mg/kg,1小时内给药)对难治性神经病理性疼痛提供有效短期镇痛,重复输注后镇痛效果更明显,但4周随访时未观察到持续镇痛。
研究设计与样本
- 利多卡因组每周静脉输注利多卡因3 mg/kg,对照组输注生理盐水,连续4周。
主要发现
- 末次输注后NRS疼痛评分较基线的百分比下降在利多卡因组显著大于对照组(P=0.011)。
- 4周随访时未检出两组NRS百分比变化的差异。
- 利多卡因组在第3次和第4次输注后NRS百分比变化的组间差异尤为明显。
- 研究参与者均未发生治疗相关的严重并发症。
关键数值与推荐
- 主要结局为基线至末次输注后11点NRS疼痛评分百分比变化,组间比较P=0.011。
- 利多卡因剂量为3 mg/kg,1小时内输注,每周1次,连续4周。
临床怎么用
- 对带状疱疹后神经痛或复杂区域疼痛综合征II型患者,可考虑每周1次利多卡因3 mg/kg输注作为短期镇痛方案。
- 重复输注可能增强短期镇痛效果,但需告知患者4周随访时镇痛未必持续。
局限性
- 原文摘要未报告样本量计算、具体P值之外的安全性数据及长期随访结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Lidocaine infusion therapy (LIT) is an effective treatment for relieving neuropathic pain (NeP). However, it remains unclear whether pain relief can be sustained through repeated lidocaine infusions. This study aimed to determine whether repeated intravenous administration of low-dose lidocaine could provide prolonged pain relief in patients with specific NeP conditions. METHODS: This is a prospective, randomized, double-blind, placebo-controlled, parallel study. We compared the efficacy and safety of lidocaine infusions (3 mg/kg) in the LIT group and normal saline infusions in the control group once a week for 4 consecutive weeks in patients with postherpetic neuralgia or complex regional pain syndrome type II. The primary outcome was the difference in the percentage change in the 11-point numerical rating scale (NRS) pain score from baseline to after the final infusion. Secondary outcomes included pain scores during 4 weeks of follow-up and any complications. RESULTS: Forty-two patients completed this study protocol. The percentage reduction in NRS pain scores after the final infusion was significantly greater in the LIT group compared with the control group (P = 0.011). However, this pain reduction was not detectable at the 4-week follow-up. The difference in the percentage change in NRS pain scores was especially prominent in the LIT group after the third and fourth infusions. None of the study participants experienced serious complications from the treatment. CONCLUSIONS: Lidocaine infusion therapy (3 mg/kg of lidocaine administered over 1 hour) provided effective short-term pain relief, which was substantially prominent after repeated infusions were administered to patients with refractory NeP. CLINICAL TRIAL REGISTRATION: This study was registered at ClinicalTrials.gov, identifier NCT02597257.
引用
- Kim YC, Castañeda AM, Lee CS, et al. Efficacy and Safety of Lidocaine Infusion Treatment for Neuropathic Pain: A Randomized, Double-Blind, and Placebo-Controlled Study. Reg Anesth Pain Med. 2018. PMID: 29381569. doi:10.1097/AAP.0000000000000741
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。